Last reviewed · How we verify
NCT05764551
The Application of Serum DNA Methylation for Patients With HCC
NA trial testing Serum DNA methylation in Hepatocellular Carcinoma in 100 participants. Status unknown.
31 March 2025
Quick facts
| Lead sponsor | Chiayi Christian Hospital |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 28 March 2023 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Serum DNA methylation
Conditions studied
- Hepatocellular Carcinoma — all drugs for Hepatocellular Carcinoma →
Sponsor
Chiayi Christian Hospital
Who can join
20 and older, any sex, with Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this single-arm prospective study is to evaluate the application of serum DNA methylation for HCC patients with normal alpha-fetoprotein. The main question it aims to answer is . Is the dynamic change of serum DNA methylation correlated to recurrence or treatment response of HCC
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Recent advances of DNA methylation in osteonecrosis of the femoral head.
Zhou T, Liu H, Li H, Zhang Y, et al · · 2025 · PMID 41104119 · DOI 10.3389/fgene.2025.1526852
Verify or expand the search:
- PubMed search for NCT05764551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT06902246 — Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT05842174 — Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma · Phase 1, PHASE2 · recruiting
- NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors · Phase 3 · recruiting
- NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer · Phase 1 · recruiting
Other Chiayi Christian Hospital trials
Trials by the same sponsor.
- NCT07251543 — Effects of a Salivary Gland Massage Program on Salivary Flow , Xerostomia, Chewing, and Swallowing, and Oral Health Amon · NA · enrolling by invitation
- NCT06823999 — Prevention and Treatment for Bruises in Patients With Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06774599 — Effects of Nonpharmacological Interventions in Sleep Quality, Anxiety, and Delirium for Patients of Adult Intensive Care · NA · not yet recruiting
- NCT06010550 — Validating a Clinical Decision Support Tool for Stratifying Stroke Risk for Dizziness/Vertigo · unknown
- NCT06076031 — Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05764551 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chiayi Christian Hospital
- Last refreshed: 21 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05764551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing